Eris Lifesciences draws ₹64.40 Cr working capital term loan from Axis Bank
Eris Lifesciences Ltd drew ₹64.40 crore from Axis Bank for short-term liabilities. The aggregate debt remains unchanged. A second charge on existing assets secures the loan.
*this image is generated using AI for illustrative purposes only.
Eris Lifesciences has drawn down a working capital term loan of ₹64.40 crore from Axis Bank Limited to meet other short-term liabilities, as disclosed in an intimation filed with stock exchanges on August 6, 2026. The company confirmed that this drawdown does not alter its aggregate debt level, indicating a restructuring or rollover of existing obligations rather than new leverage accumulation.
The transaction was executed under a sanction letter dated August 5, 2026. Axis Bank Limited will hold a second charge on assets, including both primary and collateral assets, which are already created for the company’s existing working capital credit facilities. This security arrangement ensures that the new facility is secured against the same asset base as prior borrowings.
Loan Structure and Security Details
The agreement outlines specific terms regarding the nature of the loan and the security provided. The total outstanding amounts for various loan categories were disclosed alongside the new drawdown.
| Particulars | Details |
|---|---|
| Lender | Axis Bank Limited |
| Nature of Loan | Working Capital Term Loan |
| Amount Drawn | ₹64.40 crore |
| Term Loan Outstanding | ₹91.37 crore |
| Working Capital Loan Outstanding | ₹55 crore |
| Security Provided | Second charge on existing primary and collateral assets |
| Sanction Date | August 5, 2026 |
Regulatory Compliance
The disclosure was made in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR, 2015). The filing also references Para B of Part A of Schedule III and SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
Milind Talegaonkar, Company Secretary & Compliance Officer of Eris Lifesciences, signed the intimation. The company reported no shareholding by Axis Bank in the entity, nor any related-party transaction status for this agreement. No special rights, such as director appointments or subscription rights, were granted to the lender.
Historical Stock Returns for Eris Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.24% | -3.37% | -4.90% | -2.46% | -23.77% | +84.30% |
How might the rollover of debt via this working capital term loan impact Eris Lifesciences' interest coverage ratios and overall liquidity position in the coming quarters?
Given that Axis Bank holds a second charge on assets already pledged for existing facilities, what are the potential implications for the company's ability to secure additional financing from other lenders?
Could this restructuring of short-term liabilities signal upcoming changes in Eris Lifesciences' capital allocation strategy, such as reduced capex or dividend payouts?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
